Colorado Medicaid GLP-1 Coverage Gap 2026: What Patients Need to Know

Three state Medicaid programs have carved weight-loss medications out of coverage — and Colorado is on the list by default, not by design.

Massachusetts MassHealth ends GLP-1 coverage for obesity on July 3, 2026, affecting roughly 22,000 residents. California’s Medi-Cal removed Wegovy, Zepbound, and Saxenda effective January 1, 2026. Both are “carve-outs.” That means states are actively removing obesity medications from the formulary. They are not just trimming them.

Colorado has not carved anything out. We never added it in. Health First Colorado does not cover Wegovy, Zepbound, Saxenda, Qsymia, Contrave, or Xenical for weight loss. These are excluded under Appendix P of the Preferred Drug List. GLP-1s are covered only for Type 2 diabetes. They are not covered for the disease of obesity itself.

When the headlines say “states are pulling back,” the honest version for Colorado is this: we never had it to pull. Roughly 150,000 Medicaid clients here would be eligible under proposed legislation. None are getting it today.

The Coverage Gap Is Real

Here is what I see in Greenwood Village:

A person with a BMI of 38 cannot afford $1,300 a month out of pocket for Zepbound.

A person with prediabetes and Class II obesity is told Medicaid covers the diabetes medication, but not the obesity medication.

A person who lost 60 pounds on Wegovy hits a coverage cliff and regains half of it within a year.

The pattern is consistent. Insurance routinely covers the consequences of obesity. Diabetes care, joint replacement, cardiac stents, sleep studies — all covered. But the upstream treatment? Routinely denied.

What Colorado Patients Can Actually Do

Three paths exist for people with obesity in the Denver metro:

1. Self-pay. Manufacturer savings programs can lower the monthly cost ($149 – $449 / month). Eli Lilly’s Zepbound Lilly Direct Cash Program ($299 to start, $399 for 5 mg, $449 / month for higher doses) and Novo Nordisk’s Wegovy Cash Program ($199 to start, $349 for higher doses, $399 / month for HD) are examples. Note that Oral Wegovy and Foundayo are less expensive – $149 to start, $299 / month for higher doses.
2. Medicare GLP-1 Bridge, starting July 1, 2026. CMS will offer eligible Part D beneficiaries access to certain GLP-1s for $50 per month through December 31, 2027. It is a time-limited demonstration, not a permanent benefit — but for eligible Coloradans, it is real money.
3. An obesity medicine specialist who can navigate prior authorizations, alternative medications, and combination therapy. This is what we do at Clinical Nutrition Center.

What Colorado Medicaid Actually Covers in 2026

Health First Colorado covers GLP-1 medications for Type 2 diabetes, but not for obesity. Here is the practical distinction:

• Ozempic (semaglutide 0.5 mg, 1 mg) — covered for Type 2 diabetes with prior authorization
• Mounjaro (tirzepatide) — covered for Type 2 diabetes with prior authorization
• Wegovy (semaglutide 2.4 mg) — NOT covered for weight loss under Health First Colorado
• Zepbound (tirzepatide) — NOT covered for weight loss under Health First Colorado

A patient with both obesity and prediabetes or early Type 2 diabetes may have a pathway to GLP-1 coverage through the diabetes indication, even if their primary goal is weight loss. An obesity medicine specialist can determine whether a concurrent diagnosis supports a prior authorization.

Medicare GLP-1 Bridge: Colorado Seniors in 2026

Starting July 1, 2026, Medicare Part D covers Wegovy, Zepbound, and Foundayo under the GLP-1 Bridge demonstration program at approximately 0/month for eligible beneficiaries. Key details:

• Who qualifies: Medicare Part D beneficiaries with a weight-loss indication
• Duration: Demonstration runs through December 31, 2027 — not permanent
• Prior authorization required: First submissions are commonly denied; experience with the process significantly improves approval rates

For Colorado seniors who previously paid ,000-,300/month out of pocket, this is a meaningful reduction. Working with a practice that has navigated Medicare GLP-1 Bridge authorizations improves approval odds significantly.

Colorado State Employees: A Separate Coverage Path

Effective May 1, 2026, the State of Colorado reinstated GLP-1 coverage for obesity treatment. Colorado state employees and their dependents may have coverage for Wegovy or Zepbound through their State of Colorado health plan. Read our full guide to Colorado state employee GLP-1 coverage here.

Real Patient Scenarios: Denver Metro 2026

Scenario 1: A 62-year-old Denver man with Medicare Part D, BMI of 34, and established cardiovascular disease. He likely qualifies for the Medicare GLP-1 Bridge. If approved, his monthly cost drops from approximately ,100 to 0. Next step: cardiovascular risk assessment and Medicare GLP-1 Bridge enrollment.

Scenario 2: A 38-year-old Aurora woman on Health First Colorado, BMI of 41, with prediabetes and PCOS. Ozempic or Mounjaro may be covered through her diabetes indication. If not, manufacturer savings programs offer 49-99/month as the most affordable path.

Scenario 3: A 51-year-old Highlands Ranch woman who is a Colorado state employee. Her plan reinstated GLP-1 coverage in May 2026. She should confirm formulary coverage and request a prior authorization for Wegovy or Zepbound.

How CNC Helps Colorado Patients Navigate Coverage

Clinical Nutrition Center works with patients across the Denver metro — Greenwood Village, Parker, Castle Rock, Highlands Ranch, Aurora, and Lakewood — to find the most affordable GLP-1 pathway. We assist with insurance verification, prior authorizations, manufacturer savings programs, and coverage appeals.

Schedule a coverage consultation or call us at (303) 750-9454.

The Bottom Line

The carve-outs in Massachusetts and California are a preview of the policy fight playing out in every state capitol. Colorado’s choice right now is silence. Appendix P simply excludes these drugs. Until the legislature acts, Medicaid patients in Denver, Aurora, Lakewood, and Centennial face the worst of both worlds: high obesity rates and no coverage for the most effective treatment we have.

If you are a person with obesity in Colorado and coverage is the only thing standing between you and treatment, call us. We will walk through the options that actually exist in 2026.

Dr. Lazarus Owner / Physician

Physician at Clinical Nutrition Center. Helping patients full-time with medical management of obesity and life-long weight control.

See Full Bio

Zepbound Wegovy Ozempic Mounjaro Obesity Medicine